1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6211)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13088)
  2. Department of Medicine (13004)
  3. Center for Hematologic Malignancies (10395)
  4. GSK Faculty (4422)
  5. Adult Leukemia (3583)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (775)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (204)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (431)

More Publishers

Results (13088)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies
    Meeting Abstract

    Mato, A.; Danilov, A. V.; Patel, M. R.; Tees, M. T.; Flinn, I. W.; Ai, W. Z.; Patel, K.; Wang, M.; O'Brien, S. M.; Nandakumar, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Molecular profile and clinical outcomes of renal cell carcinoma brain metastases treated with stereotactic radiosurgery
    Meeting Abstract

    Ma, J.; del Balzo, L.; Khaleel, S. S.; Flynn, J.; Zhang, Z.; Voss, M. H.; Freeman, B.; Hakimi, A. A.; Lee, C. H.; Eichholz, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205
    Meeting Abstract

    Lorusso, D.; Vergote, I.; O'Cearbhaill, R. E.; Westermann, A. M.; Banerjee, S. N.; Van Nieuwenhuysen, E.; Iglesias, D. A.; Collins, D. C.; Cibula, D.; Madsen, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)
    Meeting Abstract

    Lesokhin, A. M.; Arnulf, B.; Niesvizky, R.; Mohty, M.; Bahlis, N. J.; Tomasson, M. H.; Rodríguez-Otero, P.; Quach, H.; Raje, N. S.; Iida, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity
    Meeting Abstract

    Locke, F. L.; Siddiqi, T.; Jacobson, C. A.; Ghobadi, A.; Ahmed, S.; Miklos, D. B.; Perales, M. A.; Munoz, J.; Logan, B.; Hu, Z. H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Biomarkers of response to neoadjuvant atezolizumab with gemcitabine and cisplatin in muscle-invasive bladder cancer
    Meeting Abstract

    Lattanzi, M.; Solovyov, A.; Lihm, J.; Quinlan, C.; Whiting, K.; Li, H.; Al-Ahmadie, H. A.; Teo, M. Y.; Aggen, D. H.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm
    Meeting Abstract

    Kumar, S.; Bianchi, G.; Biran, N.; Hultcrantz, M.; Richter, J. R.; Vij, R.; Ye, J. C.; Zonder, J. A.; DiLello, L.; Yesil, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access
    Meeting Abstract

    Kourelis, T.; Bansal, R.; Patel, K. K.; Berdeja, J. G.; Raje, N. S.; Alsina, M.; Cohen, A. D.; Siegel, D. S. D.; Mailankody, S.; Htut, M.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma
    Meeting Abstract

    Kersten, M. J.; Qiao, Y.; Shah, R.; Solem, C.; Snider, J.; To, C. A.; Cheng, P.; Spooner, C.; Perales, M. A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save